Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrastaurin plus tacrolimus versus Myfortic plus tacrolimus in de novo renal transplant recipients
2009-015456-14Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2009
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sotrastaurin, tacrolimus and mycophenolate sodium in kidney allograft rejection and acute rejection (AR) (3 arms), sponsored by Novartis. Primary endpoint: Composite efficacy failure at Month 6. Started Nov 2009; status: terminated.
02
Drugs
sotrastaurintacrolimusmycophenolate sodium
03
Conditions
kidney allograft rejectionacute rejection (AR)
Beyond the preview
Go deeper on 2009-015456-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015456-14.